Loading...
•
Oct 31, 2021
KalVista Q2 2022 Earnings Report
KalVista reported results for the second fiscal quarter ended October 31, 2021, and prepared for the initiation of the KVD900 Phase 3 clinical trial and the KVD824 Phase 2 KOMPLETE clinical trial.
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the second fiscal quarter ended October 31, 2021. Research and development expenses were $17.5 million, and general and administrative expenses were $6.1 million. The net loss was $19.7 million, or $(0.80) per share. Cash, cash equivalents, and marketable securities totaled $209.8 million as of October 31, 2021.
Advanced two distinct compounds in oral hereditary angioedema franchise into later stage trials.
Initiated KOMPLETE, the Phase 2 clinical trial of KVD824, currently enrolling patients.
Presented Phase 2 data for KVD900 at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, showing rapid absorption and clinically meaningful symptom relief.
Completed an End-of-Phase 2 meeting with the FDA, confirming the Phase 3 trial design for KVD900 is expected to be appropriate to support an NDA submission.
KalVista
KalVista
Forward Guidance
KalVista is funded into at least early 2024, beyond both the KVD900 Phase 3 and KVD824 Phase 2 clinical trial data sets.